<code id='0A690D9D79'></code><style id='0A690D9D79'></style>
    • <acronym id='0A690D9D79'></acronym>
      <center id='0A690D9D79'><center id='0A690D9D79'><tfoot id='0A690D9D79'></tfoot></center><abbr id='0A690D9D79'><dir id='0A690D9D79'><tfoot id='0A690D9D79'></tfoot><noframes id='0A690D9D79'>

    • <optgroup id='0A690D9D79'><strike id='0A690D9D79'><sup id='0A690D9D79'></sup></strike><code id='0A690D9D79'></code></optgroup>
        1. <b id='0A690D9D79'><label id='0A690D9D79'><select id='0A690D9D79'><dt id='0A690D9D79'><span id='0A690D9D79'></span></dt></select></label></b><u id='0A690D9D79'></u>
          <i id='0A690D9D79'><strike id='0A690D9D79'><tt id='0A690D9D79'><pre id='0A690D9D79'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:explore    Page View:5182
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In